山河药辅 reported revenue of ¥0.52B for the period ended 2026-06-30, +10.8% year on year. Net income was ¥0.10B, a 18.6% net margin on a 32.1% gross margin. The largest revenue line is 纤维素及衍生物类 at 58% of the total. Free cash flow for the period was ¥0.07B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.52B | +10.8% |
| Gross profit | ¥0.17B | — |
| Operating income | ¥0.11B | — |
| Net income | ¥0.10B | +4.1% |
| Gross margin | 32.1% | Net margin 18.6% |
| Revenue Q/Q | -0.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 纤维素及衍生物类 | ¥0.30B | 57.9% |
| 淀粉及衍生物类 | ¥0.10B | 18.6% |
| 其他 | ¥0.08B | 15.4% |
| 无机盐类 | ¥0.04B | 8.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.35B | 67.9% |
| R&D | ¥0.02B | 4.6% |
| SG&A | ¥0.03B | 6.5% |
| Tax & other | ¥0.01B | 2.6% |
| Item | Amount |
|---|---|
| Total assets | ¥1.79B |
| Total liabilities | ¥0.69B |
| Shareholders' equity | ¥1.10B |
| Equity / assets | 61.7% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.07B |
| Cash conversion (OCF / net income) | 94% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
三鑫医疗 ・ 深信服 ・ 航天智装 ・ 赛微电子 ・ 赢合科技 ・ 全志科技 ・ 汤姆猫 ・ ST惠伦 ・ 田中精机 ・ ST华铭 ・ 迈克生物 ・ 星徽股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies